Loading...
•
Sep 30, 2020
Gossamer Bio Q3 2020 Earnings Report
Announced financial results for the third quarter of 2020 and provided a corporate update.
Key Takeaways
Gossamer Bio reported a net loss of $57.8 million for the third quarter of 2020. As of September 30, 2020, the company's cash, cash equivalents, and marketable securities totaled $555.4 million.
SHIFT-UC Phase 2 trial enrolling patients with active ulcerative colitis (UC)
TORREY Phase 2 trial activated in patients with pulmonary arterial hypertension (PAH)
Two posters with data from ongoing Phase 1/2 KEYNOTE-A36 clinical trial in advanced solid tumors presented at Society for Immunotherapy of Cancer Meeting 2020
Engaging with global regulatory authorities about forward clinical development path for an oral DP2 antagonist in moderate-to-severe asthma
Gossamer Bio
Gossamer Bio
Forward Guidance
The Company expects the combination of current cash, cash equivalents and marketable securities, and access to its debt facility will be sufficient to fund its operating and capital expenditures into the second half of 2023.